Tags : Residual

ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine)

Vartika Singh January 9, 2019

Shots: Immunogen to receive $65M as total deal value and OMERS to get royalties on sales of Kadcyla In 2015, Immunogen & IRH collaborated for Kadcyla’s royalty for $200M, where […]readmore

Tags : Residual

ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Residual

ImmunoGen to Sell Residual Royalty Rights for Kadcyla (ado-trastuzumab emtansine)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company